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Background: Venous thromboembolism (VTE) is a major cause of perioperative morbidity and mortality. Historically,
otolaryngology surgery has been seen as very low risk of VTE, given the relatively short procedures and healthy
patient population. However, head and neck surgery patients have multiple additional risk factors for VTE compared
to general otolaryngology patients, and only recently has research been directed at examining this population of
patients regarding VTE risk.
Review: VTE has long been recognized as a major issue in other surgical specialties, with VTE rates of 15–60 % in
some specialties in the absence of prophylaxis with either mechanical compression or anticoagulation. Multiple
large-scale retrospective studies have shown that the incidence of VTE in otolaryngology patients is quite low,
ranging between 0.1 and 1.6 %. However, these studies indicated that head and neck cancer patients may have
an increased risk of VTE. Further retrospective studies focusing on head and neck cancer patients found a VTE
rate of approximately 2 %, but one study also found a suspected VTE rate of 5.6 % based on clinical symptoms,
indicating that retrospective studies may underreport the true incidence. A single prospective study found a 13 %
risk of VTE after major head and neck surgery. Furthermore, risk stratification using the Caprini risk assessment
model demonstrates that the highest risk patients may have a VTE risk of 18.3 %, although this may be lowered
(but not eliminated) through the use of appropriate prophylactic anticoagulation.
Conclusion: VTE is likely a more significant concern in head and neck surgery patients than previously realized.
Appropriate prophylaxis with mechanical compression and anticoagulation is essential; risk stratification may serve
as a useful tool to identify head and neck cancer patients at highest risk for VTE.Background
Venous thromboembolism (VTE), which includes
deep vein thrombosis (DVT) and pulmonary embol-
ism (PE), is a common problem in hospitalized pa-
tients and can cause significant morbidity and
mortality. This condition is responsible for 5 to 10 %
of all hospital deaths, and is estimated to affect as
many as 600,000 patients a year in the United States
[1]. Surgery increases the risk of VTE nearly 20-fold
[2]. In the absence of prophylaxis, the estimated inci-
dence of VTE among general surgery patients is 15
to 40 % and is notably higher at 40 to 60 % in ortho-
pedic surgery patients [3]. In the setting of cancer,
surgery further doubles this risk compared to patients* Correspondence: clayburg@ohsu.edu
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depending on the type of cancer, with malignancies of
the bone, ovary, brain and liver/pancreas associated
with the highest incidences [5, 6].
In a 2003 study including over 7 million patients in
944 hospitals in the United States [7], VTE was the sec-
ond most common serious post-operative complication.
On average, a post-operative episode of VTE increases
the patient length of stay by over 5 days, resulting in
excess charges of $21,000, and has a 6.56 % excess
mortality rate. Furthermore, outpatient anticoagulation
after VTE is expensive, with 1 year of therapeutic antic-
oagulation and monitoring costing approximately
$33,000 [8]. Nevertheless, post-operative VTEs are
highly preventable and represent the most common
cause of preventable 30-day surgical mortality in patients
undergoing cancer resection [6, 9]. Consequently,
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recommended in post-operative patients [3].
The risk of VTE in general otolaryngology has been
considered to be very low, as procedures are often done
on an outpatient basis and there is no associated
immobilization or impairment of ambulation. Prior
retrospective studies of general otolaryngology patients
have demonstrated a low risk of VTE, between 0.1 and
2.4 % [10–13]. The bleeding risk associated with VTE
chemoprophylaxis also presents a unique set of compli-
cations in head and neck surgery, including airway
compromise, wound complications, and failure of micro-
vascular reconstruction. As such, compliance with VTE
chemoprophylaxis guidelines has been low among head
and neck surgeons [14]. However, patients with head
and neck cancer are intrinsically different than otherwise
healthy general otolaryngology patients, and often have
multiple risk factors for VTE development, including
malignancy, pulmonary comorbidity, large, complex sur-
geries, and other medical problems. More recent studies
have indicated that head and neck surgery patients dem-
onstrate substantially higher rates of VTE, reaching
nearly 20 % in the highest-risk subgroups [12]. The
purpose of this review is to examine the literature on
incidence and prophylaxis of VTE in head and neck
surgery patients.
Venous thromboembolism pathophysiology and
prophylaxis
In the 1800s, multiple pathologic factors—abnormal
blood flow or stasis, endothelial injury, and hypercoagul-
ability—were described as the etiologic agents for ven-
ous thrombosis. Dubbed Virchow’s triad, this provides a
framework for understanding thrombus formation.
Although an extensive list of risk factors are known for
VTE (Table 1), all these risk factors can be distilled
down to affecting one or more of these central principles
of Virchow’s Triad. A review of the molecule underpin-
nings of coagulation are outside the scope of this paper,
but have been reviewed extensively in other publications
[15–19].
Nevertheless, while the inciting mechanisms in situa-
tions of vascular injury are relatively well known, it is
somewhat less clear how thrombus formation may occur
in the setting of an intact endothelium, as occurs with
venous thromboembolism. In this setting, thrombus for-
mation is likely much more dependent upon inflamma-
tion, stasis, and/or hypercoagulability. Both cancer and
surgery are well-known to induce pro-inflammatory
states and thus induce hypercoagulability, putting post-
surgical patients, and oncologic surgical patients in
particular, at much higher risk for VTE development.
Given the significant morbidity and mortality that may
be caused by VTE, prophylaxis against VTE has beenwidely studied. Methods of VTE prophylaxis can gener-
ally be divided into two broad categories: mechanical
and pharmacologic. Pharmacologic prophylaxis includes
anticoagulants such as unfractionated heparin, low-
molecular weight heparin, fondaparinux, and warfarin.
While these drugs increase bleeding risk after surgery,
they to do provide significant protection from the devel-
opment of VTE. There is no evidence to support the use
of inferior vena cava filters in VTE prophylaxis; in fact,
not only do these filters increase the total procedure
cost, they may actually raise the risk of DVT [20]. The
American College of Chest Physicians was created
guidelines for the use of thromboprophylaxis, and this
article provides a thorough review of VTE prophylaxis
modalities and their relative risks and benefits [9].
VTE in cancer patients
The association between thromboembolism and malig-
nancy has been recognized for over 150 years. In 1865
Armand Trousseau described cancer-associated throm-
bosis and a unique alteration of the blood, thereby
recognizing the hypercoagulable state induced by malig-
nancy [21]. Approximately 20 % of cancer patients ex-
perience thrombosis at some point, and thrombosis may
be found on autopsy in up to 60 % of patients that die of
cancer [22, 23]. In a retrospective study from the
Netherlands, Blom et al. [5] found that the risk of VTE
was 12.3 per 1000 in cancer patients compared to 2 per
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lative incidence of VTE was highest for cancers of bone,
ovary, brain and pancreas. Interestingly, they also found
patients with distant metastases had a nearly two-fold
increase in relative risk VTE compared to those without
metastatic disease. Unfortunately, data for head and
neck cancer was not available in sub-group analysis,
likely due to the rarity of head and neck cancer com-
pared to more common types.
The six-fold increased incidence of venous thrombosis
in cancer patients can be attributed to baseline patient
characteristics, tumor factors, and factors relating to on-
cologic treatment. Risk factors and comorbid conditions
that are associated with head and neck cancer also play
a role in VTE formation and include older age, tobacco
use, obesity, and abnormal pulmonary function (e.g.
COPD) [3, 24]. Although the exact mechanisms by
which malignancy increases the incidence of VTE
formation have not been completely elucidated, it is
believed that inflammatory cytokines may induce endo-
thelial injury and promote a hypercoagulable state.
These procoagulants may be directly released by the
tumor, or through induction of procoagulant production
by native cells.
Venous thromboembolism in other surgical specialties
Data regarding the incidence of VTE in other surgical
specialties and evidence for chemoprophylaxis is abun-
dant, and an exhaustive review of this literature is be-
yond the scope of this paper. Historically, prospective
screening studies have demonstrated that the incidence
of asymptomatic VTE is 15–40 % in abdominal surgery
and 40–60 % in orthopedic surgery in the absence of
VTE prophylaxis [3]. However, multiple recent studies
have demonstrated an overall incidence of 1–2 % with
modern prophylaxis regimens among a heterogeneous
mix of surgical procedures [25–27]. A recent retrospect-
ive study using the American College of Surgeons
National Surgical Quality Improvement Program exam-
ined VTE after cancer surgery [6]. This study found a
1.6 % incidence of VTE in over 44,000 patients with
33.4 % of these occurring after discharge. Furthermore,
patients who experienced a VTE had a statistically sig-
nificant 6-fold (8.0 vs 1.3 %) increase in mortality.
Though this study could not attribute causality between
VTE and mortality, other studies have demonstrated
that VTE is the most-common cause of 30-day postop-
erative mortality in cancer surgery patients [27]. In a
systematic review of 25 randomized trials comparing
combined chemoprophylaxis and compression devices
with compression alone, Zereba et al. [28] demonstrated
a 44 % reduction in the risk of DVT with combined
therapy. However, the use of chemoprophylaxis also in-
creased the relative risk of bleeding by 74 %. Thus,current clinical practice guidelines recommend the use
of anticoagulation (either heparin or low molecular
weight heparin) along with compression devices in all
patients with malignancy undergoing major surgery,
unless a high risk of bleeding exists [29].
Although prophylaxis is often considered for patients
during the acute inpatient hospitalization, there is data
to suggest that anticoagulation after discharge may also
be beneficial. A prospective, placebo-controlled, double-
blind trial in which patients undergoing abdominal sur-
gery for cancer were randomized to therapy with enoxa-
parin for 4 weeks versus only 1 week showed a 60 %
decrease in venographically demonstrated thrombosis
with longer therapy [30]. Furthermore, this risk reduc-
tion in thromboembolic events was durable even 3
months after surgery. Accordingly, the American Society
of Clinical Oncology in their 2014 Clinical Practice Guide-
line recommends chemoprophylaxis in patients with
active cancer undergoing major surgery starting pre-
operatively and continuing at least 7–10 days with consid-
eration of extending therapy for up to 4 weeks [29].
Venous thromboembolism in head and neck cancer
surgery
Although it is well known that the incidence of VTE for
cancer patients is increased compared patients without
cancer, data for the incidence of VTE in head and neck
cancer patients and the need for chemoprophylaxis is
extremely limited. As previously mentioned, early
assumptions regarding VTE in surgical head and neck
cancer patients was extrapolated from general otolaryn-
gology patients. In a study from 1998, Moreano et al.
[31] examined almost 13,000 patients at a tertiary care
center and found a VTE rate of 0.3 % in general oto-
laryngology patients and 0.6 % in head and neck surgery
patients. In another more recent retrospective study
[11], approximately 6000 otolaryngology patients at a
tertiary care center were examined and only six cases
(0.1 %) of symptomatic VTE were discovered. However,
all observed VTE occurred in head and neck surgery
patients; 824 total patients had surgery for malignancy
and the 6 observed VTE yielded a rate of 0.6 %.
Although these studies hinted that head and neck sur-
gery patients may be at higher risk for VTE than general
otolaryngology patients, many previously felt that head
and neck surgery patients may be at substantially lower
risk for VTE than standard surgical oncology patients.
Unlike surgery of the chest, abdomen, pelvis, or lower
extremities that may severely limit patient mobility for
an extended period of time, head and neck surgery
patients are often able to get out of bed and ambulate
quite soon after surgery. Furthermore, the risks of antic-
oagulation in these patients may be higher, as bleeding
complications in the head and neck may have more
Ahmad and Clayburgh Cancers of the Head & Neck  (2016) 1:13 Page 4 of 8profound consequences. Hemorrhage into the airway
can rapidly prove life-threatening, and a hematoma in
the confines of the neck may easily compromise vascular
anastomoses for microvascular reconstructions. Thus,
there is concern that the risk/benefit ratio for post-
operative anticoagulation may not be as favorable in
head and neck surgery patients as that seen in other sur-
gical fields. Accordingly, the use of VTE prophylaxis by
head and neck surgeons has been exceedingly variable.
In a survey of over 600 practicing otolaryngologists,
significant variability was seen in the use of VTE prophy-
laxis, with 74 % of respondents routinely prescribing
postop SCD use, 38 % using postop compression stock-
ings, 36 % using low molecular weight heparin, and 16 %
using heparin [32].
Despite these concerns regarding VTE prophylaxis in
head and neck cancer patients, in many areas guidelines
developed in other specialties regarding the need for
VTE prophylaxis have been applied to head and neck
surgery patients. However, there is very little high-
quality data that specifically addresses VTE in head and
neck surgery patients; most studies are retrospective in
nature. A retrospective study from Australia [33] exam-
ined the incidence of VTE in 1018 patients undergoing
oncologic head and neck surgery. In this cohort, 56 % of
patients received VTE chemoprophylaxis, while the re-
mainder did not. Although the rate of VTE was 0 % in
both groups, the group receiving chemoprophylaxis had
a six-fold increase in bleeding and hematoma rate.
Garritano et al. [13] assessed 268 patients undergoing
inpatient procedures for head and neck cancer and
found an incidence 1.1 % (3/268). A study from Pakistan
[34] examined rates of VTE in 413 patients undergoing
surgery for head and neck cancer. Their overall rate of
VTE was 2.9 % despite routine prophylaxis with low mo-
lecular weight heparin. They also found that patients
who developed VTE typically had longer cases (10.8 ver-
sus 6.9 h), and involved reconstruction with a pedicled
or free flap.
However, there is an inherent issue with these retro-
spective studies, in that they may underreport the true
incidence of venous thromboembolism. These studies
would necessarily only detect those VTE that became
clinically evident around the time of surgery, and may
miss patients with either clinically silent VTE,
unrecognized/misdiagnosed VTE, or those that did not
manifest clinical symptoms until after hospital discharge.
The possibility of significant underreporting of VTE in
retrospective studies was raised by the study by Thai
et al. [35], which retrospectively examined 134 head and
neck cancer patients undergoing resection and micro-
vascular reconstruction. They found a 1.4 % (2/134) rate
of confirmed VTE as documented in the chart. However,
when other clinical symptoms were assessed that couldbe the result of VTE (i.e. leg swelling, sudden death, or
other possible sequelae of VTE without evidence of VTE
assessment in the medical record), the rate of possible
VTE rose to 5.8 % (8/134). Additionally, they showed
that strong predictors of a patient developing a VTE
included prior VTE, blood transfusion, high body mass
index, and older age. This study highlights the difficulty
with retrospective data for VTE assessment, as it
suggests that in certain high-risk groups (i.e. major
ablative surgery with microvascular reconstruction) the
rate of VTE may be higher than initially assumed.
The clear next step required to better understand VTE
risk in head and neck surgery is high-quality prospective
studies. To date, only a single prospective study has been
conducted to assess VTE incidence in head and neck
cancer surgery [24]. This study enrolled 100 consecutive
patients undergoing major surgery to treat head and
neck cancer (defined as anticipated postoperative length
of hospital stay >4 days, typically involving microvascu-
lar reconstruction or other large procedures such as
total laryngectomy). Patients received routine clinical
examination for VTE, as well as lower extremity Dop-
pler ultrasound evaluation on postoperative day 2 or 3.
Patients were also followed clinically for 30 days after
surgery. This demonstrated a 13 % overall rate of VTE
in this patient population – much higher than that seen
in previous retrospective studies. More specifically, eight
patients had clinically significant VTE (7 DVT and 1 PE)
and 5 patients had asymptomatic lower extremity super-
ficial VTE. Although routine chemoprophylaxis was not
part of the study protocol, 14 patients received anticoa-
gulation for other indications and had a higher rate of
bleeding complications (30.1 versus 5.6 %) compared to
those without anticoagulation. While this study was
designed as a pilot study rather than a full assessment of
VTE risk, and is not adequately powered to provide fur-
ther detail on VTE risk based on tumor type, surgical
procedure, or other factors, it does suggest that the true
incidence of VTE in high-risk head and neck surgery pa-
tients is higher than previously reported and may be
more similar to other high-risk surgery groups. Further
work will be needed to define the risks and benefits of
routine chemoprophylaxis on the incidence of VTE in
surgical head and neck cancer patients, and provide fur-
ther granularity regarding VTE risk in the head and neck
surgery population, such as differences between tumor
histology, subsites, procedures, and other factors.
Risk stratification in head and neck cancer patients
Given the potential risks of VTE chemoprophylaxis in
head and neck surgery patients, alongside the wide vari-
ation in reported VTE incidence rates, the optimal strat-
egy for VTE prevention in head and neck patients may
be to specifically target chemoprophylaxis towards the
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risk from the potential bleeding complications associated
with anticoagulation. Thus, there is significant interest
in risk stratifying patients for VTE. In 2001 Caprini et al.
[36] proposed a risk assessment model (RAM) for strati-
fying the risk of VTE in both surgical and non-surgical
patients. The Caprini RAM predicts the risk of VTE by
adding together points for various VTE risk factors
(Table 2). In this model, the points for each risk factor
are weighted based on their association with developing
VTE. The Caprini RAM has been validated in a retro-
spective cohort of approximately 8000 general, vascular,
and urologic surgery inpatients [37]. The risk of develop-
ing a VTE was strongly associated with the Caprini score
and is demonstrated in Table 3. Risk factors that are par-
ticularly germane to surgical head and neck cancer pa-
tients include obesity (BMI > 25), serious lung disease or
abnormal pulmonary function, advancing age, malig-
nancy and major surgery (>45 min). It is important to
note that with this tool, the difference between major
and minor surgery is defined only by time of greater
than or less than 45 min, rather than by specific proced-
ure. Based on this definition, nearly all ablative head and
neck procedures would meet the definition of major
surgery.
While the Caprini RAM was not developed specifically
for surgery, it has actually been studied most extensivelyTable 2 Caprini Risk Assessment Model
Each Risk Factor Represents 1 Point
• Age 41–60 years
• Swollen legs
• Varicose veins
• Obesity (BMI > 25)
• Minor surgery planned
• Sepsis (<1 month)
• Serious lung disease including pneumonia (<1 month)
• Acute myocardial infarction
• Congestive heart failure (<1 month)
• Medical patient currently at bed rest
• History of inflammatory bowel disease
• History of major surgery (<1 month)
• Abnormal pulmonary function (COPD)
• Pregnancy or postpartum (<1 month)
• Oral contraceptive or hormone replacement therapy
• History of unexplained stillborn infant or recurrent spontaneous abortion (>
premature birth with toxemia or growth restricted infant
Total:as a risk stratification tool in head and neck surgery.
Shuman et al. [12] retrospectively assigned Caprini
scores to 2016 otolaryngology inpatients and then exam-
ined their 30-day rate of VTE. Notably, none of these
patients received thromboprophylaxis with heparin or
low molecular weight heparin. In this study, 88 % of pa-
tients were assigned as having high (total score 3–4) or
highest (total score >5) risk, which likely reflects in in-
patient status of this population. Although the overall
30-day rate of VTE was only 1.3 %, patients with a
Caprini score of <5 had a 0.5 % incidence of VTE com-
pared to 2.4 % for patients with a score of 7–8 and
18.3 % for patients with a score >8. Evaluation of specific
risk factors revealed that patients with higher scores
were those with cancer, chronic obstructive pulmonary
disease, recent stroke, central access, and infections. The
same group later compared the above results to a cohort
of 1482 otolaryngology patients that had received
chemoprophylaxis for VTE [38]. In the cohort that re-
ceived chemoprophylaxis, the rate of overall VTE was
similar at 1.2 %. However, when patients were stratified
by Caprini score, a non-statistically significant reduction
in VTE rate was seen with chemoprophylaxis in patients
with scores between 7–8 (1.9 versus 2.4 %), and >8 (10.7
versus 18.3 %).
In another study, Yarlagadda et al. [39] retrospectively
reviewed 704 otolaryngology patients that receivedEach Risk Factor Represents 2 Points
3),
• Age 61–74 years
• Arthroscopic surgery
• Malignancy (present or previous)
• Laparoscopic surgery (>45 min)
• Patient confined to bed (>72 h)
• Immobilizing plaster cast (<1 month)
• Central venous access
• Major surgery (>45 min)
Each Risk Factor Represents 3 Points
• Age 75 years or older
• History of DVT/PE
• Positive Factor V Leiden
• Elevated serum homocysteine
• Heparin-induced thrombocytopenia
• Elevated anticardiolipin antibodies
• Other congenital or acquired thrombophilia
• Family history of thrombosis
• Positive prothrombin 20210A
• Positive Lupus anticoagulant
Each Risk Factor Represents 5 Points
• Stroke (<1 month)
• Multiple trauma (<1 month)
• Elective major lower extremity arthroplasty
• Hip, pelvis or leg fracture (<1 month)
• Acute spinal cord injury (<1 month)
Table 3 Incidence rate of VTE without routine anticoagulation
based on cumulative Caprini score [37]
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pression devices, chemoprophylaxis, or a combination)
based on institutional standards according to their
Caprini scores. In this study, the average Caprini score
was 5.7 and the overall rate of VTE was 2.1 %. As ex-
pected, patients with higher Caprini scores were found
to have higher rates VTE. The rates of VTE for patients
with Caprini scores less than 6, between 7 and 8, and
greater than 9 were 0.0, 3.0, and 13.1 % respectively.
This study also found that patients with a history of
prior VTE, malignancy, bedbound beyond 72 h, andTable 4 Studies of VTE Incidence in Otolaryngology
Source Study design Study population
Jain et al. [40]
(n = 6788)
Retrospective General otolaryngology
Chen et al. [41]
(n = 48,028)
Retrospective General otolaryngology
Lin et al. [42]
(n = 330,629)
Retrospective General otolaryngology
Moreano et al. [31]
(n = 12,805)
Retrospective General otolaryngology
Lee et al. [10]
(n = 10,176)
Retrospective General otolaryngology
Innis et al. [11]
(n = 6122)
Retrospective General otolaryngology
Garritano et al. [13]
(n = 5616)
Retrospective General otolaryngology
Shuman et al. [12]
(n = 2016)
Retrospective General otolaryngology
Yarlagadda et al. [39]
(n = 704)
Retrospective General otolaryngology
Hennessey et al. [43]
(n = 93,663)
Retrospective Head and neck cancer
Thai et al. [35]
(n = 134)
Retrospective Head and neck cancer
Chen et al. [44]
(n = 1591)
Retrospective Head and neck cancer
Ali et al. [34]
(n = 413)
Retrospective Head and neck cancer
Clayburgh et al. [24]
(n = 100)
Prospective Head and neck cancercongestive heart failure had an association with in-
creased risk of VTE.
These studies suggest that the Caprini score may be a
useful tool to risk stratify head and neck surgery patients.
There is a positive correlation between Caprini score and
incidence of VTE, and this tool may successfully identify
those patients most likely to benefit from VTE chemo-
prophylaxis. Although these studies were primarily limited
by the small numbers of patients available with high
Caprini scores, they do suggest that directing chemo-
prophylaxis towards the highest risk patients may be a
viable strategy to decrease the VTE rate, while chemo-
prophylaxis of patients with low Caprini scores is likely
unnecessary. Equally important in this data is the
realization that while appropriate chemoprophylaxis may
reduce VTE risk, it cannot entirely eliminate it; there re-
mains a subset of high-risk patients that will develop VTE
despite appropriate prophylaxis. Thus, VTE in head and
neck surgery cannot be considered a “never” event despite
appropriate preventative measures; clinical vigilance for
this complication and timely recognition and treatment
will continue to be crucial for head and neck surgeons to


























Inpatient No Overall, 1.6
Caprini score > 8, 18.3
Inpatient Yes, depending on
Caprini score
Overall, 2.1
Caprini score > 8, 13.1 %
Inpatient Unknown 2




Inpatient No Overall, 13
Clinically significant, 8
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Venous thromboembolism is a major source of peri-
operative morbidity and mortality that is largely pre-
ventable. It accounts for approximately 10 % of
hospital deaths annually [3], and patients that survive
are at risk for further complications. Although both
surgery and cancer are major risk factors for VTE,
compliance with chemoprophylaxis guidelines has
traditionally been low in head and neck surgery. This
is largely driven by the historically perceived low risk
of VTE in head and neck patients and potential for
significant complications with anticoagulation. Recent
studies have demonstrated that even though most
otolaryngology patients are considered to be at low
risk for VTE, head and neck cancer patients consti-
tute a unique group with different VTE risks (sum-
marized in Table 4). Specifically, the rate of VTE in
head and neck cancer patients is much higher than
has been reported in previous retrospective studies,
particularly in the highest-risk patients. Identification
of patients at the highest risk of VTE is vital to
appropriately direct surveillance and prevention re-
sources. As such, risk assessment models like the
Caprini RAM may be useful to identify those most
likely to benefit from chemoprophylaxis. However,
while chemoprophylaxis may reduce the risk of VTE
in high-risk groups, the risk is not eliminated, and
there is an associated increase in bleeding risk. Fur-
ther large-scale prospective trials will be necessary to
make definitive recommendations on risk stratification
and VTE prophylaxis in head and neck cancer
patients.
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